Oct 15, 2026 04:01PM
Oct 12, 2026 04:01PM
Oct 12, 2026 04:01PM
Oct 2, 2026 04:01PM
Sep 4, 2026 04:01PM
Sep 1, 2026 07:00AM
Aug 5, 2026 04:01PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 4, 2026 04:01PM
Jul 28, 2026 07:00AM
Jul 14, 2026 08:00AM
Jul 14, 2026 08:00AM
Jul 1, 2026 04:01PM
Jun 11, 2026 07:03AM
Jun 11, 2026 07:03AM Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Jun 11, 2026 07:02AM
Jun 11, 2026 07:00AM
Jun 4, 2026 04:01PM
Jun 4, 2026 07:00AM
Jun 4, 2026 07:00AM
Jun 2, 2026 04:01PM
Jun 2, 2026 04:01PM Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Jun 1, 2026 07:00AM
Jun 1, 2026 07:00AM
May 21, 2026 05:01PM
May 21, 2026 05:01PM
May 20, 2026 07:00AM
May 12, 2026 10:31AM
May 6, 2026 04:01PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 30, 2026 04:01PM
Apr 24, 2026 07:00AM
Apr 3, 2026 04:01PM
Mar 4, 2026 04:01PM
Feb 26, 2026 04:01PM
Feb 23, 2026 07:00AM
Feb 19, 2026 07:00AM Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
Feb 5, 2026 07:00AM
Feb 4, 2026 04:01PM
Jan 12, 2026 07:08AM
Jan 12, 2026 07:00AM
Jan 7, 2026 07:00AM
Jan 5, 2026 07:00AM
Dec 12, 2025 07:00AM Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
Dec 9, 2025 04:34AM
Dec 8, 2025 06:50AM
Dec 8, 2025 06:50AM
Dec 3, 2025 04:01PM
Dec 1, 2025 07:00AM
Nov 5, 2025 04:01PM
Nov 3, 2025 04:01PM Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 3, 2025 09:09AM

334,274 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All